Document Detail


Effects of voltage-gated K+ channel blockers in gefitinib-resistant H460 non-small cell lung cancer cells.
MedLine Citation:
PMID:  23225427     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Voltage-gated K(+) (Kv) channels are known to be associated with the proliferation of several types of cancer cells, including lung adenocarcinoma cells, and certain Kv channel blockers inhibit cancer cell proliferation. In the present study, we investigated the effects of Kv channel blockers in gefitinib-resistant H460 non-small cell lung cancer (NSCLC) cells. Treatment with dendrotoxin-κ (DTX-κ), which is a Kv1.1-specific blocker, reduced H460 cell viability and arrested cells in G(1)/S transition during cell-cycle progression. We administered DTX-κ in a xenograft model using nude mice. The tumor volume was reduced by the injection of DTX-κ into the tumor tissues compared to the control group. These results indicate that DTX-κ has antitumor effects in gefitinib-resistant H460 cells through the pathway governing the G(1)/S transition both in vitro and in vivo. These findings suggest that Kv1.1 could serve as a novel therapeutic target for gefitinib-resistant NSCLC.
Authors:
Won Il Jeon; Pan Dong Ryu; So Yeong Lee
Related Documents :
23414137 - Expression and regulation of α-transducin in the pig gastrointestinal tract.
24528787 - Enhanced detection of metastatic prostate cancer cells in human plasma with lipid bodie...
23494437 - Formulation of selected renal cells for implantation into a kidney.
23370387 - Sperm(idine) answers the next generation.
11193347 - Differentiation of hamster liver oval cell following clonorchis sinensis infection.
3885217 - Stimulation of na+/h+ antiport is an early event in hypertrophy of renal proximal tubul...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Anticancer research     Volume:  32     ISSN:  1791-7530     ISO Abbreviation:  Anticancer Res.     Publication Date:  2012 Dec 
Date Detail:
Created Date:  2012-12-10     Completed Date:  2013-05-02     Revised Date:  2013-11-02    
Medline Journal Info:
Nlm Unique ID:  8102988     Medline TA:  Anticancer Res     Country:  Greece    
Other Details:
Languages:  eng     Pagination:  5279-84     Citation Subset:  IM    
Affiliation:
DVM, Laboratory of Veterinary Pharmacology, College of Veterinary Medicine, Seoul National University, 599 Gwanak-ro, Gwanak-gu, Seoul, 151-742, South Korea.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adenocarcinoma / drug therapy,  genetics,  metabolism,  pathology
Animals
Antineoplastic Combined Chemotherapy Protocols / pharmacology*
Carcinoma, Non-Small-Cell Lung / drug therapy*,  genetics,  metabolism,  pathology
Cell Cycle / drug effects
Cell Growth Processes / drug effects
Cell Line, Tumor
Drug Resistance, Neoplasm
Drug Synergism
Humans
Kv1.1 Potassium Channel / antagonists & inhibitors*,  biosynthesis,  genetics,  metabolism
Lung Neoplasms / drug therapy*,  genetics,  metabolism,  pathology
Male
Mice
Mice, Nude
Peptides / administration & dosage,  pharmacology*
Quinazolines / administration & dosage,  pharmacology*
RNA, Messenger / biosynthesis,  genetics
Xenograft Model Antitumor Assays
Chemical
Reg. No./Substance:
0/Peptides; 0/Quinazolines; 0/RNA, Messenger; 119128-61-9/dendrotoxin K; 147173-20-4/Kv1.1 Potassium Channel; S65743JHBS/gefitinib
Comments/Corrections
Erratum In:
Anticancer Res. 2013 Sep;33(9):4135-6

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Effects of structural modifications of daunorubicin on in vitro antileukemic activity.
Next Document:  The Effect of High-intensity Focused Ultrasound in Combination with Cisplatin Using a Xenograft Mode...